Relmada reports a PhIII fail, blaming 'paradoxical' placebo effect — shares wiped
A Florida biotech attempting to develop a rapid-acting antidepressant ran face-first into a brick wall Thursday.
Relmada Therapeutics reported a Phase III fail for its lead compound, REL-1017, in major depressive disorder, noting the program did not separate from placebo after 28 days in a depression rating scale measuring severe episodes. Though the data were numerically similar, Relmada did not report a p-value to illustrate by how much REL-1017 whiffed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.